G1 Therapeutics

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

G1 Therapeutics excels in Q4 with Cosela sales surge and optimistic 2023 outlook

G1 Therapeutics delivered strong financial results in Q4 2022, driven by the impressive performance of Cosela in the small cell lung cancer market. Despite organizational changes to conserve capital, the company remains focused on growth and innovation. With a solid cash balance projection for 2023 and a growing customer base, G1 Therapeutics is poised for continued success.

G1 Therapeutics reports robust Q1 performance and optimistic growth outlook

G1 Therapeutics demonstrated strong financial performance and commercial growth in Q1 2023, with COSELA showing promising results and a positive outlook for the future.
While facing challenges related to potential drug interactions, the company is well-positioned to capitalize on opportunities through upcoming data readouts and strategic decisions.
Investors can be optimistic about G1 Therapeutics' continued progress, supported by a solid financial foundation and a focus on maximizing COSELA's potential.

G1 Therapeutics reports resilient Q2 performance amidst challenges and opportunities

G1 Therapeutics delivered a strong financial performance in Q2 2023, showcasing resilience and strategic financial management amidst challenges.
The company's focus on advancing its clinical pipeline and securing survival results in early 2024 positions it for future growth and value creation.
While facing challenges such as a chemotherapy shortage and operational efficiency, G1 Therapeutics maintains stability and confidence in its financial outlook.
Opportunities lie in capitalizing on COSELA sales growth, advancing clinical programs, and leveraging financial flexibility for sustained growth and innovation.

G1 Therapeutics overcomes supply challenges, eyes growth in oncology

G1 Therapeutics exhibited resilience in revenue growth despite challenges with COSELA's market supply, showcasing operational strength.
The company's strong financial position and cost management efforts bode well for sustainable growth and value creation.
Exciting opportunities in clinical trials and market expansion present avenues for future success and competitive positioning in the oncology sector.

G1 Therapeutics excels in Q4 2023, poised for growth ahead

G1 Therapeutics demonstrated strong performance in Q4 2023 with notable revenue growth and expense management.
COSELA's market share and promising trial results highlight strengths in the product portfolio.
While challenges like trial result anticipation and cost efficiency persist, opportunities for growth and optimization are evident.
Overall, G1 Therapeutics shows promise with a healthy cash position and positive sales guidance for 2024.

G1 Therapeutics reports strong Q1 earnings and diversifies revenue streams

G1 Therapeutics delivered robust financial results, showcasing growth in revenue and cost management improvements in Q1 2024.
While facing challenges in managing expenses and advancing clinical trials, the company remains optimistic about revenue guidance and market opportunities.
With a solid cash position and strategic partnerships, G1 Therapeutics is well-positioned to drive future growth and innovation in the oncology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

G1 Therapeutics, Inc. is a commercial-stage oncology firm focused on the research and marketing of next-generation anticancer treatments.

G1 Therapeutics Inc. (NASDAQ:GTHX ) Q4 2022 Earnings Conference Call March 1, 2023 8:30 AM ET Company Participants Jack Bailey - Chief Executive Officer Jennifer Moses - Chief Financial Officer Raj Malik - Chief Medical Officer Andrew Perry - Chief Commercial Officer Will Roberts - Vice President, Communications Conference Call Participants Gil Blum - Needham & Co. Joseph Thome - Cowen & Co. Dane Leone - Raymond James Priyanka Grover - JP Morgan Operator Good day and welcome to the G1 Therapeutics fourth quarter financial results conference call. At this time, all participants are in a listen-only mode.

G1 Therapeutics (GTHX) Q4 2022 Earnings Call Transcript

- Achieved $31.3 Million in Net Revenue from Sales of COSELA® (trilaciclib) for Full Year 2022, Representing 182% Growth Over 2021; Provided 2023 Net COSELA Revenue Guidance of $50 to $60 Million -

G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on March 7th, 2023, at 10:30 AM EST, G1's Chief Executive Officer Jack Bailey will participate in the moderated Breast and Lung Cancer Panel during the Cowen 43rd Annual Health Care Conference.

G1 Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the fourth quarter and full year 2022 on Wednesday, March 1, 2023, at 8:30 a.m. ET.

G1 Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 1, 2023

BARK

EMCORE

Iris Energy Ltd

Penny stocks to buy according to 4 analysts in the stock market in February 2023. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 4 To Watch With Targets Up To 397%

G1 Therapeutics (GTHX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

G1 Therapeutics (GTHX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

The shares of G1 Therapeutics Inc (NASDAQ:GTHX) were last seen down 53.6% at $3.33, after the company announced plans to discontinue a drug study for the treatment of a type of colon cancer , with placebo outperforming the drug in anti-tumor efficacy data.

Pharma Stock Hits Record Low Due to Pulled Study

G1 Therapeutics (NASDAQ: GTHX ) stock is falling on Monday after the company released results from a Phase 3 clinical trial. The bad news bringing GTHX stock down today is the company choosing to end discontinue the colorectal ( CRC ) trial.

Why Is G1 Therapeutics (GTHX) Stock Down 52% Today?

- PRESERVE 1 Achieved its Co-Primary Endpoints Showing Statistically Significant Reductions in Occurrence of Severe Neutropenia During Induction and Duration of Severe Neutropenia in Cycles 1 Through 4 -

G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)

- COSELA®, the world's first and only myeloprotection drug, was prescribed in Jilin Cancer Hospital on January 28, 2023 - Simcere delivers drug to patients in 908 days from execution of license agreement to first prescription NANJING, China , Feb. 9, 2023 /PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) ("Simcere"), an innovative global biopharmaceutical company, and G1 Therapeutics, Inc., (Nasdaq: GTHX) ("G1 Therapeutics"), a commercial-stage oncology company, announce a significant milestone in the fight against cancer with the issuance of the first prescription for COSELA® (trilaciclib) in China. COSELA is a first-in-class FDA and NMPA-approved therapy indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).

First Prescription for COSELA® (trilaciclib) Issued in China

G1 shares have experienced much volatility in the past year. Regardless of volatility, the lead drug (Cosela) generates increased revenue for the lung cancer franchise. Recent data for the Phase 2 (PRESERVE 3) trial that assesses Cosela for bladder cancer was negative.

G1 Therapeutics: Poised For A Turnaround

RESEARCH TRIANGLE PARK, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on January 19th, 2023, at 11:30 AM EST, G1's Chief Executive Officer Jack Bailey will provide a corporate presentation during the virtual 2023 B. Riley Securities 3rd Annual Oncology Conference.

G1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology Conference

- Initial Results from Pivotal Phase 3 PRESERVE 1 Trial in Colorectal Cancer Expected in February 2023; Positive Results Would Initiate Regulatory Interactions for Label Expansion -

G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib

RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided an initial update on PRESERVE 3, an ongoing Phase 2, randomized, open-label study of first-line platinum-based chemotherapy and maintenance therapy with the immune checkpoint inhibitor, avelumab, administered alone, or in combination with trilaciclib, in patients with untreated, locally advanced or metastatic urothelial carcinoma (mUC). Additional safety and efficacy data, including the primary endpoint of progression free survival (PFS), are anticipated in the middle of 2023.

G1 Therapeutics Provides Initial Update on Phase 2 Bladder Cancer Trial; Progression Free Survival (PFS) Data Expected in Mid-2023

RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on January 11, 2023, at 1:30 PM PST, G1's Chief Executive Officer Jack Bailey will provide a corporate presentation during the 41st Annual J.P. Morgan Healthcare Conference.

G1 Therapeutics to Participate in the 41st Annual J.P. Morgan Conference

RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided initial results from a 24 patient Phase 2 mechanism of action (MOA) trial showing favorable alterations in the tumor microenvironment from a single dose of trilaciclib monotherapy as measured by increases in the proportions of CD8+ T cells compared to T regulatory cells (Tregs) in patients with early-stage triple negative breast cancer (TNBC). These initial study results are being presented in a poster session at the annual San Antonio Breast Cancer Symposium (SABCS), December 6 - 10, 2022.

Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment

RESEARCH TRIANGLE PARK, N.C., Nov. 23, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1's Chief Executive Officer, and other members of the executive team will participate virtually in the Evercore ISI HealthCONx Conference. The fireside chat with G1 will be held at 1:25PM EST on November 30, 2022. The webcast and replay of this event will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.

G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference

RESEARCH TRIANGLE PARK, N.C., Nov. 22, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the closing of an underwritten public offering of 7,700,000 shares of its common stock at a public offering price of $6.50 per share. G1 Therapeutics received $50,050,000 in gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses. In addition, G1 Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 shares of common stock at the public offering price, less the underwriting discount. Cowen and Raymond James acted as joint book-running managers for the offering. Needham & Company and Wedbush PacGrow acted as lead managers for the offering.

G1 Therapeutics Announces Closing of Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the pricing of an underwritten public offering of 7,700,000 shares of its common stock at a public offering price of $6.50 per share, for total gross proceeds of $50,050,000. All of the shares in the offering will be sold by G1 Therapeutics. In addition, G1 Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 shares of common stock at the public offering price, less the underwriting discount. The offering is expected to close on November 22, 2022, subject to customary closing conditions.

G1 Therapeutics Announces Pricing of Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it has commenced an underwritten public offering of its common stock. All of the shares in the offering will be sold by G1 Therapeutics. In addition, G1 Therapeutics expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock at the public offering price less the underwriting discount.

G1 Therapeutics Announces Proposed Public Offering of Common Stock

G1 Therapeutics, Inc. (NASDAQ:GTHX ) Q3 2022 Earnings Conference Call November 2, 2022 8:30 AM ET Company Participants Will Roberts - VP, Communications Jack Bailey - CEO Raj Malik - CMO Andrew Perry - CCO Jen Moses - CFO Conference Call Participants Gil Blum - Needham & Company Dane Leone - RJF Ed White - H.C. Wainwright Malcolm Kuno - JPM David Nierengarten - Wedbush PacGrow Troy Langford - Cowen and Company Tony Butler - ROTH Capital Partners Operator Hello and thank you for standing by.

G1 Therapeutics, Inc. (GTHX) Q3 2022 Earnings Call Transcript

G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 7.81% and 4.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

G1 Therapeutics (GTHX) Reports Q3 Loss, Tops Revenue Estimates

- Achieved $23.6 million in Total Revenue in the Third Quarter of 2022 Including $8.3 million in Net Revenue from Sales of COSELA® (trilaciclib) -

G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights

- Data Suggest On-Target Effect of Trilaciclib May Reduce Rates of Myelosuppression, Diarrhea, and Potentially Alopecia Associated with Sacituzumab Govitecan-Hziy - - Data Suggest On-Target Effect of Trilaciclib May Reduce Rates of Myelosuppression, Diarrhea, and Potentially Alopecia Associated with Sacituzumab Govitecan-Hziy -

Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC)

Here is how G1 Therapeutics (GTHX) and HealthEquity (HQY) have performed compared to their sector so far this year.

News for G1 Therapeutics Stock (GTHX)